Cerenome (CNSY) vs SkyAI (SKYA)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
SkyAI (SKYA) has outperformed Cerenome (CNSY) over the past year, losing 23.0% versus a loss of 95.2%. SkyAI is the larger company by market cap ($7.8 million vs $6.2 million), about 1.3 times the size. Cerenome converts more of its revenue into profit, with a net margin of -429.4% versus -138400.0%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | CNSY | SKYA |
|---|---|---|
| Share price | $0.6301 | $2.18 |
| Market cap | $6.16M | $7.82M |
| 1-day change | -10.29% | -45.50% |
| YTD return | -95.06% | +7.39% |
| 1-year return | -95.24% | -22.97% |
| 5-year return | -99.89% | — |
| P/E ratio (TTM) | — | 2.83 |
| EPS (TTM) | $-3.50 | $0.77 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $5.21M | $204.12K |
| Revenue growth (YoY) | -10.49% | — |
| Net income (latest FY) | $-22.39M | $-282.50M |
| Gross margin | — | -202.49% |
| Operating margin | -293.46% | -132145.49% |
| Net margin | -429.43% | -138400.02% |
| 52-week high | $19.00 | $4.39 |
| 52-week low | $0.43 | $0.91 |
| Distance from 52-week high | -96.68% | -50.34% |
| Analyst consensus | strong_buy | — |
| Avg. price target upside | +4304.06% | — |
| Average volume | 804.18K | 1.74M |
| Shares outstanding | 9.78M | 3.59M |
| Employees | 28 | 30 |
| Sector | Health Care | Health Care |
| Industry | Medical/Dental Instruments | Medical/Dental Instruments |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- SKYA has outperformed CNSY by 72.3 percentage points over the past year.
- Cerenome is more profitable, keeping -429.4 cents of every revenue dollar as net income versus -138400.0 cents for SkyAI.
About Cerenome
CNSY stock →Cerenome, Inc., a clinical-stage pharmaceutical company, focuses on the development, manufacture, and commercialization of treatments for patients with cancer. The company's lead radiotherapeutic candidate is rhenium obisbemeda, a patented radiotherapy for patients with central nervous system and other cancers, including recurrent glioblastoma, leptomeningeal metastases, and pediatric brain cancers.
Health Care · Medical/Dental Instruments · 28 employees
About SkyAI
SKYA stock →SkyAI, Inc., a financial technology company with a Solana digital asset treasury that is building an agentic finance platform. It combines stablecoin rails with AI to deliver financial access, education, and actionable intelligence to the underbanked users in Asia, Latin America, and Africa.
Health Care · Medical/Dental Instruments · 30 employees
CNSY vs SKYA FAQ
Which is bigger, Cerenome or SkyAI?
SkyAI (SKYA) is larger, with a market capitalization of $7.82M compared with $6.16M for Cerenome (CNSY).
Which stock has performed better over the past year, CNSY or SKYA?
SKYA returned -22.97% over the past 12 months, compared with -95.24% for CNSY (price return, excluding dividends). Past performance does not predict future results.
Are Cerenome and SkyAI in the same industry?
Yes. Both are classified in the Medical/Dental Instruments industry within the Health Care sector.